J&J/Veridex’ CellSearch System Paves Way For FDA Class II Designation
This article was originally published in The Gray Sheet
Executive Summary
FDA formally classifies immunomagnetic circulating cancer cell selection and enumeration systems as Class II with special controls in a May 11 final rule